**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 85389

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia**

Ma J *et al.* Patients with schizophrenia

Jing Ma, Xue-Qin Song

**Jing Ma,** First Department of Mood Disorders, The Second Affiliated Hospital of Xinxiang Medical College, Xinxiang 453000, Henan Province, China

**Xue-Qin Song,** Department of Psychiatry, The First Affiliated of Zhengzhou University, Zhengzhou 450052, Henan Province, China

**Author contributions:** Ma J and Song XQ designed the study; Ma J wrote the manuscript; Ma J and Song XQ collected and analyzed the data; Ma J and Song XQ revised and reviewed the manuscript; All authors have read and approved the final manuscript.

**Corresponding author: Xue-Qin Song, PhD, Chief Physician,** Department of Psychiatry, The First Affiliated of Zhengzhou University, No. 1 Jian Dong Road, Zhengzhou 450052, Henan Province, China. sxq907907@163.com

**Received:** June 6, 2023

**Revised:** August 8, 2023

**Accepted:** August 15, 2023

**Published online:** October 19, 2023

**Abstract**

BACKGROUND

The gut microbiome interacts with the central nervous system through the gut-brain axis, and this interaction involves neuronal, endocrine, and immune mechanisms, among others, which allow the microbiota to influence and respond to a variety of behavioral and mental conditions.

AIM

To explore the correlation between cognitive impairment and gut microbiota imbalance in patients with schizophrenia.

METHODS

A total of 498 untreated patients with schizophrenia admitted to our hospital from July 2020 to July 2022 were selected as the case group, while 498 healthy volunteers who underwent physical examinations at our hospital during the same period were selected as a control group. Fluorescence *in situ* hybridization was employed to determine the total number of bacteria in the feces of the two groups. The cognitive function test package was used to assess the score of cognitive function in each dimension. Then, the relationship between gut microbiota and cognitive function was analyzed.

RESULTS

There were statistically significant differences in the relative abundance of gut microbiota at both phylum and class levels between the case group and the control group. In addition, the scores of cognitive function, such as attention/alertness and learning ability, were significantly lower in the case group than in the control group (all *P* < 0.05). The cognitive function was positively correlated with Actinomycetota, Bacteroidota, Euryarchaeota, Fusobacteria, Pseudomonadota, and Saccharibacteria, while negatively correlated with Bacillota, Tenericutes, and Verrucomicrobia at the phylum level. While at the class level, the cognitive function was positively correlated with Class Actinobacteria, Bacteroidia, Betaproteobacteria, Proteobacteria, Blastomycetes, and Gammaproteobacteria, while negatively correlated with Bacilli, Clostridia, Coriobacteriia, and Verrucomicrobiae.

CONCLUSION

There is a relationship between the metabolic results of gut microbiota and cognitive function in patients with schizophrenia. When imbalances occur in the gut microbiota of patients, it leads to more severe cognitive impairment.

**Key Words:** Schizophrenia; Cognitive function; Gut microbiota; Metabolic imbalance; Bacteria

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Ma J, Song XQ. Correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia. *World J Psychiatry* 2023; 13(10): 724-731

**URL:** https://www.wjgnet.com/2220-3206/full/v13/i10/724.htm

**DOI:** https://dx.doi.org/10.5498/wjp.v13.i10.724

**Core Tip:** The highlights of this study are as follows. First, individuals with schizophrenia have imbalanced intestinal microbiota compared to healthy individuals. Second, patients with schizophrenia exhibit cognitive impairments in various areas such as attention, memory, social cognition, and executive function. Additionally, specific microbial groups such as Actinomycetes, Bacteroides, and Proteobacteria have shown a positive correlation with cognitive function in patients with schizophrenia. Furthermore, there is a close relationship between metabolic imbalance of intestinal flora and cognitive impairment in individuals with schizophrenia. Lastly, further clinical trials are necessary to gather more data and insights for the development of effective treatments for schizophrenia.

**INTRODUCTION**

Schizophrenia is a severe mental disorder with unknown etiology. Most of the patients are young and middle-aged. Frequently, the patients may encounter various obstacles in thinking, perception, emotion, and behavior, leading to a lack of coordination between mental activities and the surroundings[1]. Patients with schizophrenia exhibit characteristics such as a high disability rate, substantial burden, and an increased tendency of suicide. This disorder also causes hallucinations, delusions, language, and behavior abnormalities, with a long course and heterogeneous clinical manifestations. Schizophrenia has an impact on the physical and mental health, as well as social quality of life for patients, resulting in economic pressure and social burden. With the continuous advancement of biological technology, the understanding of schizophrenia is gradually deepening[2,3]. As one of the primary symptoms of schizophrenia, cognitive dysfunction includes two aspects, mental cognition and social cognition. Generally, it manifests before other psychotic symptoms of schizophrenia and persists throughout the course of the disease[4]. In recent years, there has been an increasing focus on the cognitive impairment of patients. Cognitive impairment can impede patients' social and occupational rehabilitation, and assessing cognitive function can predict the disease progression and treatment response[5]. Gut microbiota constitutes a complex and vast ecosystem. Scholars have proposed that gut microbiota can regulate the immune and inflammatory responses within the human body and influence neural development. However, the understanding of the relationship between gut microbiota and schizophrenia is still limited[6,7].

In this study, cognitive function and gut microbiota were examined to explore the potential correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia.

**MATERIALS AND METHODS**

***Materials***

A total of 498 patients with schizophrenia admitted to The First Affiliated Hospital of Zhengzhou University from July 2020 to July 2021 were selected as the case group, and 498 healthy volunteers who underwent physical examination at the same hospital were randomly chosen as the control group.

Inclusion criteria were: patients who met the diagnostic criteria for schizophrenia in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition[8], patients with no abnormality in routine blood tests, and patients who were 18-years-old to 50-years-old.

Exclusion criteria were: patients with diabetes, thyroid disease, hypertension, heart disease, or other diseases that may affect the stability of gut microbiota; patients who suffered from diarrhea in the past 3 mo; or patients who were pregnant or lactating.

***Determination of bacterial counts***

The bacterial counts in patients were determined using fluorescence *in situ* hybridization. We utilized fluorescent tags as a substitute for isotope labeling. First, biotin labeling was carried out, followed by DNA probe hybridization. Next, fluorescein avidin was used to bind with the probe hybridization to the target DNA on the chromosomes to form a hybrid. Qualitative and quantitative analyses were then performed after detecting the fluorescence under a microscope.

***Cognitive function scores***

The first step was to determine whether the patient was conscious. Generally, the Glasgow scale was employed to assess the degree of consciousness disturbance. If the patient was conscious, the Short Form Mental State Examination was used to screen for cognitive dysfunction. Based on the results, the presence of cognitive impairment could be identified, and further assessment of cognitive function was conducted accordingly.

***Statistical processing***

SPSS21.0 software was used for the data analyses. The independent *t*-test was used for comparisons between the two groups. For multivariate regression analysis, the multiple linear regression model was employed when the dependent variable was continuous, whereas the logistic regression model was used when the dependent variable was dichotomous. *P* < 0.05 was considered statistically significant.

**RESULTS**

***Distribution of gut microbiota at the phylum level in the two groups***

As shown in Table 1, the case group exhibited a significantly higher relative abundance of Actinomycetota, Bacteroidota, Euryarchaeota, Fusobacteria, Pseudomonadota, and lower abundance of Bacillota, Tenericutes, and Verrucomicrobia when compared with the control group (*P* < 0.05).

***Distribution of gut microbiota at the class level in the two groups***

As shown in Table 2, compared with the control group, the case group exhibited a significantly higher relative abundance of Class Actinobacteria, Bacteroidia, Betaproteobacteria, Proteobacteria, Blastomycetes, and Gammaproteobacteria, and lower relative abundance of Bacilli, Clostridia, Coriobacteriia, and Verrucomicrobiae (*P* < 0.05).

***Comparison of cognitive scores between the two groups***

As shown in Table 3, the scores of attention or alertness, learning, memory, fine motors, social cognition, executive function, conversion, inhibition, planning, working memory, category fluency, information processing, and total cognitive score were all significantly lower in the case group than in the control group (*P* < 0.05).

***Correlation analysis between cognitive function and gut microbiota at the phylum level***

As shown in Table 4, cognitive function was positively correlated with Actinomycetota (*r* = 6.591, *P* = 0.001), Bacteroidota (*r* = 5.625, *P* = 0.016), Euryarchaeota (*r* = 6.281, *P* = 0.183), Fusobacteria (*r* = 2.190, *P* = 0.026), Pseudomonadota (*r* = 6.364, *P* = 0.018), and Saccharibacteria (*r* = 5.196, *P* = 0.037), while negatively correlated with Bacillota (*r* = -0.976, *P* = 0.281), Tenericutes (*r* = -0.623, *P* = 0.001), and Verrucomicrobia (*r* = -0.191, *P* = 0.006).

***Correlation analysis of between cognitive function and gut microbiota at the class level***

As shown in Table 5, cognitive function was positively correlated with Class Actinobacteria (*r* = 3.257, *P* = 0.001), Bacteroidia (*r* = 6.294, *P* = 0.001), Betaproteobacteria (*r* = 6.281, *P* = 0.016), Proteobacteria (*r* = 6.270, *P* = 0.008), Blastomycetes (*r* = 5.671, *P* = 0.006), and Gammaproteobacteria (*r* = 4.195, *P* = 0.005), while negatively correlated with Bacilli (*r* = -0.981, *P* = 0.001), Clostridia (*r* = -0.124, *P* = 0.015), Coriobacteriia (*r* = -0.293, *P* = 0.019), and Verrucomicrobiae (*r* = -0.549, *P* = 0.010).

**DISCUSSION**

Schizophrenia is a chronic and severe mental disorder characterized by disturbances in an individual's sensory, emotional, and behavioral functions[9]. Patients with schizophrenia have difficulties distinguishing between reality and the imaginary. They may exhibit slow reactions, and show a phenomenon of behavioral withdrawal, significantly affecting their ability to engage in normal social behavior. In medical terms, schizophrenia is classified as a disorder rather than a disease. This disorder often typically occurs during the young or prime stages of life. It encompasses disturbances in the body, mind, emotions, and behaviors, but the patients do not have a coma or mentally retarded imagination[10,11]. Some studies have found that genetic factors, brain structure, and environment factors contribute significantly to the development of this disorder. Therefore, comprehensive medical and psychological treatments are necessary to address the multifaceted nature of the condition.

Cognitive impairment is commonly observed in patients with schizophrenia, impacting various aspects such as information integration, memory, and attention. Symptoms of cognitive dysfunction are prominently manifested through memory decline in the general population[12,13]. In addition to memory decline, schizophrenia can result in impairments in executive function, visuospatial ability, comprehension, and numeracy. People's general cognition and social cognition are also closely associated with age. As the aging population continues to grow, the incidence of cognitive dysfunction is increasing[14,15]. A large number of clinical studies have demonstrated a certain correlation between schizophrenia and cognitive function. Effective interventions targeting overall cognition, emotions, and society aspects have shown promising results. In this study, patients with schizophrenia exhibited considerable declines in various cognitive aspects, including learning, memory, fine motor skills, social cognition, working memory, category fluency, information processing, and kinetic energy, when compared to healthy individuals. These results suggest association between cognitive function and schizophrenia, which is similar to the results of the above research.

Schizophrenia has profoundly impacted numerous families. Consequently, there is a paramount need to pursue effective treatment options and improve the patient prognosis[16]. Gut microbiota is a central regulator of metabolism in the human body and has been found to be associated with various mental diseases[17,18]. In modern society, there is a growing awareness of the diversity, complexity, and dynamics of gut microbiota. Differences in the structure and diversity of gut microbiota have been observed in patients with schizophrenia, with the control of the disorder having a great impact on the distribution of gut microbiota structure[19,20]. Some scholars have noted that alterations in the gut microbial community can affect the cytokine levels in the body, subsequently impacting the brain function and behaviors, and greatly affecting the prognosis of patients. In this study, we found that the relative abundance of gut microbiota in patients with schizophrenia differed significantly from that in healthy individuals, indicating an imbalance in the gut microbiota in patients with schizophrenia, which is consistent with the previous results. This article examined gut microbiota at a phylum level (Actinomycetota, Bacteroidota, Euryarchaeota, Fusobacteria, Pseudomonadota, *etc*) and a class level (Class Actinobacteria, Bacteroidia, Betaproteobacteria, Proteobacteria, Blastomycetes, and Gammaproteobacteria, *etc*). The results suggest that there is a certain correlation between gut microbiota and schizophrenia.

In this study, a correlation was identified between cognitive impairment and metabolic imbalance of gut microbiota. However, it is essential to acknowledge that the small sample size in this study may introduce some bias in the data. In the future, clinical trials with larger sample size should be conducted to provide more reliable data to guide the clinical treatment for patients with schizophrenia.

**CONCLUSION**

To summarize, this study revealed the presence of gut microbiota imbalance in schizophrenia patients and found the correlation between cognitive impairment and metabolic imbalance of gut microbiota in these patients. of intestinal flora, providing insights into the link between changes in gut microbiota and cognitive function, as well as the pathogenesis of schizophrenia. This research presents a novel approach that may pave the way for future treatments targeting schizophrenia.

**ARTICLE HIGHLIGHTS**

***Research background***

Schizophrenia is a severe mental disorder characterized by impaired thinking, perception, emotion, and behavior. It affects the physical and mental health of the patients, leading to a high disability rate, burden, and suicide tendency. Cognitive dysfunction is a primary symptom of schizophrenia and includes mental cognition and social cognition. It can significantly impact the overall functioning and quality of life of individuals with schizophrenia. In recent years, there has been increasing recognition of the importance of cognitive function in schizophrenia. Cognitive impairment can not only predict the progression of the disease but also affect the treatment response and functional outcomes. Therefore, understanding the factors that contribute to cognitive impairment in schizophrenia is crucial for improving patient outcomes. Gut microbiota, a complex ecosystem of microorganisms residing in the gastrointestinal tract, has been found to play a role in regulating immune and inflammatory responses, as well as influencing neural development. Emerging evidence has suggested a potential connection between gut microbiota and psychiatric disorders, including schizophrenia. However, the specific relationship between gut microbiota and cognitive impairment in schizophrenia patients remains limited and requires further exploration.

***Research motivation***

Recent research has suggested a potential link between gut microbiota and psychiatric disorders, including schizophrenia. However, the specific relationship between gut microbiota and cognitive impairment in schizophrenia remains poorly understood. This knowledge gap necessitates further investigation to explore the potential role of gut microbiota in the cognitive dysfunction observed in schizophrenia.

The motivation behind this study is to bridge this gap by investigating the correlation between cognitive impairment and gut microbiota imbalance in patients with schizophrenia. By examining the composition of gut microbiota and evaluating cognitive function in a large sample of untreated schizophrenia patients, we aimed to shed light on the potential mechanisms underlying cognitive dysfunction in this population.

The findings of this study provide significant clinical implications and contribute to the development of novel therapeutic strategies targeting the gut microbiota to improve cognitive outcomes of patients with schizophrenia. Ultimately, this research aims to enhance the understanding of the complex interplay between gut microbiota and cognitive impairment in schizophrenia, leading to improved diagnosis, treatment, and overall management of this mental disorder.

***Research objectives***

The objective of this research was to explore the correlation between cognitive impairment and gut microbiota imbalance in patients with schizophrenia. The study compared the composition and abundance of gut microbiota in untreated schizophrenia patients and healthy controls, evaluated cognitive function using a consensus version of the cognitive function test package, and examined the relationship between specific microbial groups and cognitive function.

***Research methods***

The research employed a case-control study design. A total of 498 untreated schizophrenia patients admitted to the hospital from July 2020 to July 2022 were selected as the case group, while 498 healthy volunteers who underwent physical examinations at the same hospital during the same period served as the control group. The composition and abundance of gut microbiota were assessed using fluorescence *in situ* hybridization to determine the total number of bacteria in fecal samples from both groups. Cognitive function was evaluated using a cognitive function test package consensus version, which assesses various dimensions of cognitive function. Statistical analysis was performed to compare the relative abundance of actinomycetes and other microbial groups between the case and control groups, as well as to examine the relationship between specific gut microbiota and cognitive function. The statistical significance level was set at *P* < 0.05.

***Research results***

The research findings revealed the correlation between gut microbiota and cognitive function in patients with schizophrenia. There was a statistically significant difference in the relative abundance of Actinomycetota between the case group and the control group, indicating an imbalance in the gut microbiota of schizophrenia patients. Moreover, compared to the control group, the schizophrenia patients demonstrated statistically significant differences in scores related to attention/alertness, and learning ability, suggesting impaired cognitive function in these areas. Furthermore, specific microbial groups showed correlations with cognitive function: Actinomycetota, Bacteroidota, Fusobacteria, and Proteobacteria were found to be positively associated with cognitive function, while the Coriobacteriia showed a negative correlation. These findings provide evidence of the influence of gut microbiota on cognitive impairment in schizophrenia patients and underscore the importance of addressing gut microbiota imbalance as a potential therapeutic target for improving cognitive outcomes in this population.

***Research conclusions***

In conclusion, this research confirmed a relationship between gut microbiota metabolic imbalance and cognitive function in patients with schizophrenia. The study findings indicate that when there is an imbalance in the composition of gut microbiota, the cognitive function of schizophrenia patients is more severely affected. The relative abundance of Actinomycetota was found to significantly differ between the case group and the control group, suggesting an imbalance in gut microbiota in schizophrenia patients. Additionally, specific microbial groups, including Actinomycetota, Bacteroidota, Fusobacteria, and Proteobacteria, were positively correlated with cognitive function, while the Coriobacteriia showed a negative correlation. These results emphasize the importance of addressing gut microbiota imbalances as a potential target for improving cognitive impairment in schizophrenia patients. Further research and interventions focused on modulating gut microbial composition and promoting gut health may lead to improved cognitive outcomes in this population.

***Research perspectives***

In future research, it is recommended to conduct longitudinal studies to observe changes in gut microbiota and cognitive function over time in schizophrenia patients, as well as intervention studies to investigate the effects of modulating gut microbiota on cognitive outcomes. Mechanistic studies can provide insights into the underlying mechanisms of the gut-brain axis in schizophrenia. The identification of specific gut microbiota markers as diagnostic or prognostic biomarkers for cognitive impairment, exploring individual differences, and developing personalized therapeutic strategies are also important areas for further investigation. By pursuing these research perspectives, we can advance our understanding of the role of gut microbiota in schizophrenia-related cognitive impairment and potentially develop targeted interventions to improve cognitive outcomes in this population.

**REFERENCES**

1 **McCutcheon RA**, Reis Marques T, Howes OD. Schizophrenia-An Overview. *JAMA Psychiatry* 2020; **77**: 201-210 [PMID: 31664453 DOI: 10.1001/jamapsychiatry.2019.3360]

2 **Khavari B**, Cairns MJ. Epigenomic Dysregulation in Schizophrenia: In Search of Disease Etiology and Biomarkers. *Cells* 2020; **9** [PMID: 32764320 DOI: 10.3390/cells9081837]

3 **Jauhar S**, Johnstone M, McKenna PJ. Schizophrenia. *Lancet* 2022; **399**: 473-486 [PMID: 35093231 DOI: 10.1016/S0140-6736(21)01730-X]

4 **Xu C**, Tao X, Ma X, Zhao R, Cao Z. Cognitive Dysfunction after Heart Disease: A Manifestation of the Heart-Brain Axis. *Oxid Med Cell Longev* 2021; **2021**: 4899688 [PMID: 34457113 DOI: 10.1155/2021/4899688]

5 **Oset M**, Stasiolek M, Matysiak M. Cognitive Dysfunction in the Early Stages of Multiple Sclerosis-How Much and How Important? *Curr Neurol Neurosci Rep* 2020; **20**: 22 [PMID: 32444997 DOI: 10.1007/s11910-020-01045-3]

6 **Zhou B**, Yuan Y, Zhang S, Guo C, Li X, Li G, Xiong W, Zeng Z. Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract. *Front Immunol* 2020; **11**: 575 [PMID: 32318067 DOI: 10.3389/fimmu.2020.00575]

7 **Tang Q**, Cao L. [Intestinal flora and neurological disorders]. *Sheng Wu Gong Cheng Xue Bao* 2021; **37**: 3757-3780 [PMID: 34841782 DOI: 10.13345/j.cjb.210253]

8 **Somma A**, Adler LA, Gialdi G, Arteconi M, Cotilli E, Fossati A. The Validity of the World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition in Adolescence. *J Child Adolesc Psychopharmacol* 2021; **31**: 631-638 [PMID: 34166067 DOI: 10.1089/cap.2020.0158]

9 **Lu Y**, Yuan X, Wang M, He Z, Li H, Wang J, Li Q. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. *J Hematol Oncol* 2022; **15**: 47 [PMID: 35488243 DOI: 10.1186/s13045-022-01273-9]

10 **Buckley PF**. Neuroinflammation and Schizophrenia. *Curr Psychiatry Rep* 2019; **21**: 72 [PMID: 31267432 DOI: 10.1007/s11920-019-1050-z]

11 **Zamanpoor M**. Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. *Psychiatr Genet* 2020; **30**: 1-9 [PMID: 31764709 DOI: 10.1097/YPG.0000000000000245]

12 **Harvey PD**, Bosia M, Cavallaro R, Howes OD, Kahn RS, Leucht S, Müller DR, Penadés R, Vita A. Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. *Schizophr Res Cogn* 2022; **29**: 100249 [PMID: 35345598 DOI: 10.1016/j.scog.2022.100249]

13 **Stogios N**, Gdanski A, Gerretsen P, Chintoh AF, Graff-Guerrero A, Rajji TK, Remington G, Hahn MK, Agarwal SM. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. *NPJ Schizophr* 2021; **7**: 22 [PMID: 33903594 DOI: 10.1038/s41537-021-00151-6]

14 **Roy DS**, Zhang Y, Aida T, Choi S, Chen Q, Hou Y, Lea NE, Skaggs KM, Quay JC, Liew M, Maisano H, Le V, Jones C, Xu J, Kong D, Sullivan HA, Saunders A, McCarroll SA, Wickersham IR, Feng G. Anterior thalamic dysfunction underlies cognitive deficits in a subset of neuropsychiatric disease models. *Neuron* 2021; **109**: 2590-2603.e13 [PMID: 34197733 DOI: 10.1016/j.neuron.2021.06.005]

15 **Wu Q**, Wang X, Wang Y, Long YJ, Zhao JP, Wu RR. Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia. *Neurosci Bull* 2021; **37**: 1609-1624 [PMID: 34227057 DOI: 10.1007/s12264-021-00740-6]

16 **Correll CU**. Using Patient-Centered Assessment in Schizophrenia Care: Defining Recovery and Discussing Concerns and Preferences. *J Clin Psychiatry* 2020; **81** [PMID: 32297720 DOI: 10.4088/JCP.MS19053BR2C]

17 **Stępnicki P**, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. *Molecules* 2018; **23** [PMID: 30127324 DOI: 10.3390/molecules23082087]

18 **Gomaa EZ**. Human gut microbiota/microbiome in health and diseases: a review. *Antonie Van Leeuwenhoek* 2020; **113**: 2019-2040 [PMID: 33136284 DOI: 10.1007/s10482-020-01474-7]

19 **Jia X**, Xu W, Zhang L, Li X, Wang R, Wu S. Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia. *Front Cell Infect Microbiol* 2021; **11**: 634780 [PMID: 34490132 DOI: 10.3389/fcimb.2021.634780]

20 **Chen Y**, Zhou J, Wang L. Role and Mechanism of Gut Microbiota in Human Disease. *Front Cell Infect Microbiol* 2021; **11**: 625913 [PMID: 33816335 DOI: 10.3389/fcimb.2021.625913]

**Footnotes**

**Institutional review board statement:** The study was approved by the Ethics Committee of The First Affiliated of Zhengzhou University.

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 6, 2023

**First decision:** June 21, 2023

**Article in press:** August 15, 2023

**Specialty type:** Psychiatry

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cipriani A, United Kingdom; Dragano N, Germany **S-Editor:** Lin C **L-Editor:** Filipodia **P-Editor:** Chen YX**Table 1 Relative abundance of gut microbiota at the phylum level in the two groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name of bacteria** | **Case group, *n* = 498** | **Control group, *n* = 498** | ***T* value** | ***P* value** |
| Actinomycetota | 2.95 ± 5.62 | 2.18 ± 3.60 | 2.575 | 0.010 |
| Bacteroidota | 34.27 ± 19.53 | 26.84 ± 16.07 | 6.556 | 0.001 |
| Euryarchaeota | 0.16 ± 0.57 | 0.00 ± 0.00 | 6.264 | 0.001 |
| Bacillota | 48.82 ± 17.96 | 61.37 ± 14.49 | 12.140 | 0.001 |
| Fusobacteria | 0.08 ± 0.57 | 0.02 ± 0.07 | 2.332 | 0.019 |
| Pseudomonadota | 15.82 ± 20.13 | 7.68 ± 11.59 | 7.820 | 0.001 |
| Saccharibacteria | 0.49 ± 0.27 | 0.01 ± 0.01 | 39.650 | 0.001 |
| Tenericutes | 0.23 ± 1.14 | 0.59 ± 1.92 | 3.598 | 0.001 |
| Verrucomicrobia | 0.57 ± 1.94 | 1.62 ± 5.19 | 4.229 | 0.001 |

Data are presented as mean ± SD.

**Table 2 Relative abundance of gut microbiota at the class level in the two groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name of bacteria** | **Case group, *n* = 498** | **Control group, *n* = 498** | ***T* value** | ***P* value** |
| Class Actinobacteria | 2.81 ± 5.64 | 1.56 ± 2.81 | 4.427 | 0.001 |
| Bacilli | 2.01 ± 4.28 | 2.67 ± 5.60 | 2.090 | 0.036 |
| Bacteroidia | 31.28 ± 19.67 | 26.68 ± 16.18 | 4.030 | 0.001 |
| Betaproteobacteria | 1.50 ± 3.29 | 0.39 ± 0.52 | 7.437 | 0.001 |
| Clostridia | 45.92 ± 18.62 | 58.18 ± 13.92 | 11.770 | 0.001 |
| Coriobacteriia | 0.21 ± 0.49 | 0.58 ± 1.29 | 5.984 | 0.001 |
| Proteobacteria | 0.29 ± 0.39 | 0.15 ± 0.24 | 6.822 | 0.001 |
| Blastomycetes | 0.96 ± 1.19 | 0.67 ± 1.20 | 3.829 | 0.01 |
| Gammaproteobacteria | 13.84 ± 19.67 | 6.92 ± 11.37 | 6.797 | 0.001 |
| Verrucomicrobiae | 0.58 ± 1.69 | 1.82 ± 5.86 | 4.537 | 0.001 |

Data are presented as mean ± SD.

**Table 3 Comparative analysis of cognitive scores between the two groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cognitive domain** | **Case group, *n* = 498** | **Control group, *n* = 498** | ***T* value** | ***P* value** |
| Attention/alertness | 40.27 ± 6.29 | 51.98 ± 9.92 | 22.250 | 0.001 |
| Learning | 36.27 ± 10.01 | 50.69 ± 10.08 | 22.650 | 0.001 |
| Memory | 40.31 ± 11.26 | 54.27 ± 7.19 | 23.320 | 0.001 |
| Fine motors | 37.29 ± 13.27 | 59.06 ± 7.91 | 31.450 | 0.001 |
| Social cognition | 41.09 ± 11.08 | 54.26 ± 10.87 | 18.930 | 0.001 |
| Executive function | 40.18 ± 7.04 | 52.37 ± 5.09 | 31.310 | 0.001 |
| Conversion | 41.06 ± 7.21 | 49.57 ± 7.61 | 18.120 | 0.001 |
| Inhibition | 38.62 ± 9.51 | 54.63 ± 9.67 | 26.340 | 0.001 |
| Planning | 42.14 ± 13.01 | 52.67 ± 10.17 | 14.230 | 0.001 |
| Working memory | 42.09 ± 13.02 | 53.19 ± 9.06 | 15.620 | 0.001 |
| Category fluency | 39.86 ± 10.05 | 53.18 ± 9.07 | 21.960 | 0.001 |
| Information processing | 33.43 ± 9.14 | 48.45 ± 7.39 | 28.520 | 0.001 |
| Total score | 40.64 ± 7.17 | 51.14 ± 5.29 | 26.300 | 0.001 |

Data are presented as mean ± SD of points.

**Table 4 Correlation analysis between the total cognitive score and gut microbiota at the phylum level**

|  |  |  |
| --- | --- | --- |
| **Name of bacteria** | **Total cognitive score** | |
| ***R* value** | ***P* value** |
| Actinomycetota | 6.591 | 0.001 |
| Bacteroidota | 5.625 | 0.016 |
| Euryarchaeota | 6.281 | 0.183 |
| Bacillota | 0.976 | 0.281 |
| Fusobacteria | 2.190 | 0.026 |
| Pseudomonadota | 6.364 | 0.018 |
| Saccharibacteria | 5.196 | 0.037 |
| Tenericutes | 0.623 | 0.001 |
| Verrucomicrobia | 0.191 | 0.006 |

**Table 5 Correlation analysis between the total cognitive score and gut microbiota at the class level**

|  |  |  |
| --- | --- | --- |
| **Name of bacteria** | **Total cognitive score** | |
| ***R* value** | ***P* value** |
| Actinobacteria | 3.257 | 0.001 |
| Bacilli | 0.981 | 0.001 |
| Bacteroidia | 6.294 | 0.001 |
| Betaproteobacteria | 6.281 | 0.016 |
| Clostridia | 0.124 | 0.015 |
| Coriobacteriia | 0.293 | 0.019 |
| Proteobacteria | 6.270 | 0.008 |
| Blastomycetes | 5.671 | 0.006 |
| Gammaproteobacteria | 4.195 | 0.005 |
| Verrucomicrobiae | 0.549 | 0.010 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**